Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
1.530
-0.160 (-9.47%)
At close: Nov 1, 2024, 4:00 PM
1.560
+0.030 (1.96%)
After-hours: Nov 1, 2024, 5:45 PM EDT
Taysha Gene Therapies Revenue
Taysha Gene Therapies had revenue of $1.11M in the quarter ending June 30, 2024, a decrease of -53.57%. This brings the company's revenue in the last twelve months to $12.87M, up 34.05% year-over-year. In the year 2023, Taysha Gene Therapies had annual revenue of $15.45M with 517.55% growth.
Revenue (ttm)
$12.87M
Revenue Growth
+34.05%
P/S Ratio
23.80
Revenue / Employee
$247,558
Employees
52
Market Cap
313.56M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 15.45M | 12.95M | 517.55% |
Dec 31, 2022 | 2.50M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
OraSure Technologies | 273.54M |
Aurora Cannabis | 203.84M |
Treace Medical Concepts | 198.53M |
Spok Holdings | 137.71M |
Jin Medical International | 20.13M |
AC Immune | 17.24M |
TSHA News
- 22 hours ago - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 11 days ago - Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress - GlobeNewsWire
- 19 days ago - Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data - Seeking Alpha
- 2 months ago - Taysha Gene Therapies, Inc. (TSHA) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 4 months ago - Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
- 4 months ago - Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire